Clindamycin Topical Gel 1% — Competitive Intelligence Brief

Clindamycin Topical Gel 1% (Clindamycin Topical Gel 1%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lincosamide antibiotic. Area: Dermatology.

marketed Lincosamide antibiotic Bacterial 50S ribosomal subunit Dermatology Small molecule

Target snapshot

Clindamycin Topical Gel 1% (Clindamycin Topical Gel 1%) — Jinnah Postgraduate Medical Centre. Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby reducing acne-causing bacteria and decreasing inflammation in acne lesions.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Clindamycin Topical Gel 1% TARGET	Clindamycin Topical Gel 1%	Jinnah Postgraduate Medical Centre	marketed	Lincosamide antibiotic	Bacterial 50S ribosomal subunit
CLDM 1% gel	CLDM 1% gel	GlaxoSmithKline	marketed	Lincosamide antibiotic	Bacterial 50S ribosomal subunit
Erythromycin, Azithromycin , Clarithromycin	Erythromycin, Azithromycin , Clarithromycin	Baqiyatallah Medical Sciences University	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
AzaSite®	AzaSite®	Merck Sharp & Dohme LLC	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Azithropycin according to symptoms	Azithropycin according to symptoms	University Hospital, Montpellier	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit (23S rRNA)
Linezolid (L)	Linezolid (L)	Shenzhen Third People's Hospital	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
Azithromycin Ophthalmic Solution, 1%	Azithromycin Ophthalmic Solution, 1%	Merck Sharp & Dohme LLC	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Lincosamide antibiotic class)

1. GlaxoSmithKline · 2 drugs in this class
2. Balmoral Medical company · 1 drug in this class
3. Generic (originally Upjohn/Pfizer) · 1 drug in this class
4. Hospital General Universitario Elche · 1 drug in this class
5. Janssen-Cilag, S.A. · 1 drug in this class
6. Jinnah Postgraduate Medical Centre · 1 drug in this class
7. Oral and Maxillofacial Surgery Clinic, Poland · 1 drug in this class
8. Stiefel, a GSK Company · 1 drug in this class
9. Actavis Inc. · 1 drug in this class
10. University of Toronto · 1 drug in this class